Submitted hESC Lines Pending Review - NIH Human Embryonic Stem Cell Registry
U.S. Department of Health & Human Services Logo
NIH > Office of Extramural Research Logo
Home About Grants Funding Forms & Deadlines Grants Policy News & Events About OER NIH Home
Grants and Funding

NIH Human Embryonic Stem Cell Registry
Submitted hESC Lines Pending Review

The following is a list of human embryonic stem cell lines submitted to NIH, which are PENDING review to determine if they may be used in NIH funded research.

Pending Lines: 
Sorted by:
Date/Time: 		85  (in 48 Submissions)
Cell Line Name
05/07/2013 at 04:09 AM
Cell Line Name Ascending Sort Organization Date Submitted
CL1 Technion R&D foundation 03/12/2013
CR-4 University of Texas Hlth Sci Ctr at Houston 09/13/2012
CSC14 California Stem Cell, Inc. 11/09/2012
GENEA015 Genea 04/04/2013
GENEA016 Genea 04/04/2013
GENEA042 Genea 04/04/2013
GENEA043 Genea 04/04/2013
GENEA047 Genea 04/04/2013
GENEA052 Genea 04/04/2013
GENEA057 Genea 04/04/2013
GENEA077 Genea 04/04/2013
GENEA078 Genea 04/04/2013
GENEA079 Genea 04/04/2013
GENEA080 Genea 04/04/2013
GENEA081 Genea 04/04/2013
GENEA082 Genea 04/04/2013
GENEA083 Genea 04/04/2013
GENEA084 Genea 04/04/2013
GENEA085 Genea 04/04/2013
GENEA086 Genea 04/04/2013
GENEA087 Genea 04/04/2013
GENEA088 Genea 04/04/2013
GENEA089 Genea 04/04/2013
GENEA090 Genea 04/04/2013
GENEA091 Genea 04/04/2013
GENEA096 Genea 04/04/2013
GENEA097 Genea 04/04/2013
GENEA098 Genea 04/04/2013
HSF6 University of California San Francisco 09/07/2012
KC013; disease-specific mutation King's College London 04/16/2013
KCL011 King's College London 04/16/2013
KCL012 ; disease-specific mutation King's College London 04/16/2013
KCL015; disease-specific mutation King's College London 04/16/2013
KCL016; disease-specific mutation King's College London 04/16/2013
KCL017; disease-specific mutation King's College London 04/16/2013
KCL018; disease-specific mutation King's College London 04/16/2013
KCL019 King's College London 04/17/2013
KCL020 King's College London 04/17/2013
KCL021; disease-specific mutation King's College London 04/16/2013
KCL022 King's College London 04/17/2013
KCL023 King's College London 04/17/2013
KCL024; disease-specific mutation King's College London 04/16/2013
KCL025 King's College London 04/16/2013
KCL026; disease-specific mutation King's College London 04/16/2013
KCL027; disease-specific mutation King's College London 04/16/2013
KCL028 King's College London 04/16/2013
KCL029; disease-specific mutation King's College London 04/16/2013
KCL030; disease-specific mutation King's College London 04/16/2013
KCL031 King's College London 04/17/2013
KCL032 King's College London 04/17/2013
KCL033 King's College London 04/17/2013
KCL034 King's College London 04/17/2013
KCL035 King's College London 04/16/2013
KCL036; disease-specific mutation King's College London 04/16/2013
KCL037 King's College London 04/17/2013
KCL038 King's College London 04/17/2013
KCL039 King's College London 04/17/2013
KCL040 King's College London 04/17/2013
KCL041; disease-specific mutation King's College London 04/17/2013
KCL042; disease-specific mutation King's College London 04/16/2013
KCL043; disease-specific mutation King's College London 04/16/2013
MA 09 Advanced Cell Technology, Inc. * 12/30/2009
MA 42 Advanced Cell Technology, Inc. 02/04/2010
MA 50 Advanced Cell Technology, Inc. 02/04/2010
NED 1 Advanced Cell Technology, Inc. * 12/24/2009
NED 2 Advanced Cell Technology, Inc. * 12/24/2009
NED 3 Advanced Cell Technology, Inc. * 12/24/2009
NED 4 Advanced Cell Technology, Inc. * 12/24/2009
NYUES10 New York University School of Medicine 04/19/2013
NYUES11 New York University School of Medicine 04/19/2013
NYUES12 New York University School of Medicine 04/19/2013
NYUES13 New York University School of Medicine 04/19/2013
NYUES8 New York University School of Medicine 04/19/2013
NYUES9 New York University School of Medicine 04/19/2013
UCSFB1 University of California San Francisco * 12/04/2009
UCSFB10 University of California San Francisco * 12/04/2009
UCSFB2 University of California San Francisco * 12/04/2009
UCSFB3 University of California San Francisco * 12/04/2009
UCSFB4 University of California San Francisco * 12/04/2009
UCSFB5 University of California San Francisco * 12/04/2009
UCSFB6 University of California San Francisco * 12/04/2009
UCSFB7 University of California San Francisco * 12/04/2009
UCSFB8 University of California San Francisco * 12/04/2009
UCSFB9 University of California San Francisco * 12/04/2009
WCMC-37; disease-specific mutation Joan & Sanford I. Weill Medical College of Cornell University 11/05/2012

* This cell line is ineligible for review under the NIH Guidelines for Human Stem Cell Research because the line was derived from a pre-blastocyst embryo. The Guidelines define human embryonic stem cells as "cells that are derived from the inner cell mass of blastocyst stage human embryos..." NIH has proposed a change to this definition, and therefore has not deleted this submission from the "Pending Review" list.


Total Pending Lines = 85


Go to NIH Form 2890 Login Page

Go to NIH Stem Cell Information Page


   
Related Resources

    NIH Form 2890:

  • Login Page
    (Authorization Required)
    Contact Us:

  • Email questions to:
    hescregistry@mail.nih.gov

    • (Emails that are offensive or unrelated to stem cells will be deleted.)
 

This page last updated on July 13, 2011
Content Manager: stemcell@mail.nih.gov
Technical Issues: E-mail OER Webmaster

Social Media Links